Sedana Medical AB (publ)

OM:SEDANA Stock Report

Market Cap: SEK 1.6b

Sedana Medical Balance Sheet Health

Financial Health criteria checks 5/6

Sedana Medical has a total shareholder equity of SEK950.0M and total debt of SEK0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are SEK998.2M and SEK48.2M respectively.

Key information

0%

Debt to equity ratio

SEK 0

Debt

Interest coverage ration/a
CashSEK 226.39m
EquitySEK 949.99m
Total liabilitiesSEK 48.24m
Total assetsSEK 998.24m

Recent financial health updates

Recent updates

There's Reason For Concern Over Sedana Medical AB (publ)'s (STO:SEDANA) Massive 26% Price Jump

Dec 12
There's Reason For Concern Over Sedana Medical AB (publ)'s (STO:SEDANA) Massive 26% Price Jump

kr34.00: That's What Analysts Think Sedana Medical AB (publ) (STO:SEDANA) Is Worth After Its Latest Results

Oct 28
kr34.00: That's What Analysts Think Sedana Medical AB (publ) (STO:SEDANA) Is Worth After Its Latest Results

Sedana Medical AB (publ)'s (STO:SEDANA) 36% Cheaper Price Remains In Tune With Revenues

Oct 25
Sedana Medical AB (publ)'s (STO:SEDANA) 36% Cheaper Price Remains In Tune With Revenues

After Leaping 27% Sedana Medical AB (publ) (STO:SEDANA) Shares Are Not Flying Under The Radar

Jun 07
After Leaping 27% Sedana Medical AB (publ) (STO:SEDANA) Shares Are Not Flying Under The Radar

Sedana Medical AB (publ) Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Apr 28
Sedana Medical AB (publ) Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Here's Why We're Not Too Worried About Sedana Medical's (STO:SEDANA) Cash Burn Situation

Mar 16
Here's Why We're Not Too Worried About Sedana Medical's (STO:SEDANA) Cash Burn Situation

Optimistic Investors Push Sedana Medical AB (publ) (STO:SEDANA) Shares Up 34% But Growth Is Lacking

Dec 21
Optimistic Investors Push Sedana Medical AB (publ) (STO:SEDANA) Shares Up 34% But Growth Is Lacking

We're Hopeful That Sedana Medical (STO:SEDANA) Will Use Its Cash Wisely

Oct 29
We're Hopeful That Sedana Medical (STO:SEDANA) Will Use Its Cash Wisely

Sedana Medical (STO:SEDANA) Is In A Good Position To Deliver On Growth Plans

Jul 12
Sedana Medical (STO:SEDANA) Is In A Good Position To Deliver On Growth Plans

Analysts Just Made A Major Revision To Their Sedana Medical AB (publ) (STO:SEDANA) Revenue Forecasts

May 01
Analysts Just Made A Major Revision To Their Sedana Medical AB (publ) (STO:SEDANA) Revenue Forecasts

We're Hopeful That Sedana Medical (STO:SEDANA) Will Use Its Cash Wisely

Feb 17
We're Hopeful That Sedana Medical (STO:SEDANA) Will Use Its Cash Wisely

Analysts Are More Bearish On Sedana Medical AB (publ) (STO:SEDANA) Than They Used To Be

Jan 20
Analysts Are More Bearish On Sedana Medical AB (publ) (STO:SEDANA) Than They Used To Be

Here's Why We're Not Too Worried About Sedana Medical's (STO:SEDANA) Cash Burn Situation

Oct 05
Here's Why We're Not Too Worried About Sedana Medical's (STO:SEDANA) Cash Burn Situation

Companies Like Sedana Medical (STO:SEDANA) Are In A Position To Invest In Growth

Jul 05
Companies Like Sedana Medical (STO:SEDANA) Are In A Position To Invest In Growth

Sedana Medical AB (publ) (STO:SEDANA) Analysts Just Slashed This Year's Estimates

May 03
Sedana Medical AB (publ) (STO:SEDANA) Analysts Just Slashed This Year's Estimates

Financial Position Analysis

Short Term Liabilities: SEDANA's short term assets (SEK308.8M) exceed its short term liabilities (SEK44.7M).

Long Term Liabilities: SEDANA's short term assets (SEK308.8M) exceed its long term liabilities (SEK3.5M).


Debt to Equity History and Analysis

Debt Level: SEDANA is debt free.

Reducing Debt: SEDANA had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SEDANA has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if SEDANA has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/18 02:34
End of Day Share Price 2025/01/17 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sedana Medical AB (publ) is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter ÖstlingPareto Securities
Filip WibergPareto Securities
Oscar BergmanRedeye